We previously showed that monocytes and fibroblasts from SSc patients are deficient in caveolin-1, and that treatment of these cells with the CSD peptide compensates for this deficiency thereby reversing a number of pathological features of these cells. This evidence concerns the gene CAV1 and systemic sclerosis.